Related Experiment Video
Updated: Jul 13, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[Targeting CD20 in rheumatoid arthritis].
Kazuyoshi Saito1, Yoshiya Tanaka
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 24, 2007
Summary
Treatment with rituximab, a CD20 antibody, offers significant relief for rheumatoid arthritis (RA) patients who have not responded to tumor necrosis factor (TNF) blockers. This therapy shows high efficacy and tolerability in managing refractory RA.
Area of Science:
- Immunology
- Rheumatology
Context:
- Rheumatoid arthritis (RA) is an autoimmune condition causing joint inflammation and bone damage.
- Current treatments like methotrexate and TNF blockers are effective but not for all patients.
- Patients refractory to TNF blockers lack established treatment options.
Purpose:
- To evaluate the efficacy and tolerability of CD20 antibody therapy in patients with RA who failed previous anti-TNF treatments.
Summary:
- Rituximab, an anti-CD20 monoclonal antibody, was administered to patients with active, long-standing RA and inadequate response to anti-TNF therapies.
- Concomitant methotrexate therapy was used.
- Significant and clinically meaningful improvements in disease activity were observed.
Impact:
- CD20 antibody therapy, such as rituximab, presents a viable and effective treatment option for refractory RA.
- This finding addresses an unmet need in managing patients with severe RA who have exhausted other treatment avenues.
- The study supports the use of rituximab for its excellent tolerability and high efficacy in this patient population.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...